Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Translational Model to Predict Pulmonary Pharmacokinetics and Efficacy in Man for Inhaled Bronchodilators

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: HENDRICKX, Adriaan (AstraZeneca, DMPK, Mölndal, Sweden)
  • Co-author(s): Adriaan Hendrickx: RIA DMPK, AstraZeneca, Mölndal, Sweden
    Eva Lamm Bergström: RIA DMPK, AstraZeneca, Mölndal, Sweden
    David L. I. Janzén: CVMD DMPK, AstraZeneca, Mölndal, Sweden
    Markus Fridén: RIA DMPK, AstraZeneca, Mölndal, Sweden
    Ulf Eriksson: RIA QCP, AstraZeneca, Mölndal, Sweden
    Ken Grime: RIA DMPK, AstraZeneca, Mölndal, Sweden
    Douglas Ferguson: Oncology DMPK, AstraZeneca, Mölndal, Sweden
  • Abstract:

    Backgrounds

    Inhaled drug therapy is typically used for targeting the lung whilst minimizing systemic exposure in order to improve the benefit/risk margin for treatments of respiratory disease.

    Aims

    The aim of current study was to develop a translational modelling framework for capturing both lung and systemic PK and efficacy after pulmonary delivery

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses